Last reviewed · How we verify
Oxalobacter formigenes
At a glance
| Generic name | Oxalobacter formigenes |
|---|---|
| Also known as | - Oxabact(tm), - OC3, Oxabact, OC3, OC5 |
| Sponsor | OxThera |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Oxalobacter Formigenes Colonization and Urinary Oxalate Excretion (NA)
- O. Formigenes Colonization in Calcium Oxalate Kidney Stone Disease (NA)
- Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria (PHASE3)
- An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria (PHASE3)
- Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria (PHASE1, PHASE2)
- Phase 2/3 Oxabact Study (PHASE2, PHASE3)
- Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |